ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3056

Increased Circulating Th17 Cells, Serum IL-17 and Serum IL-23 in Takayasu’s Arteritis

Ramnath Misra, Durga Prasanna Misra and Smriti Chaurasia, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: IL-23, interleukins (IL) and takayasu arteritis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Vasculitis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

The immune mechanisms underlying Takayasu’s arteritis (TA) are not clear. Expanded Th17 T cell subset has been demonstrated in Giant Cell Arteritis. Gamma delta T cells (γδT), natural killer cells (NK) and natural killer -T cells (NKT) are also producers of IL-17 besides Th17 cells. Studies have demonstrated an increased number of circulating γδT cells in peripheral blood and in histopathology of arterial biopsies of patients with TA. We therefore enumerated Th17, γδT , NK and NKT cells and serum levels of IL-17 and IL23 in peripheral blood of patients with TA, and looked for its correlation with disease activity and erythrocyte sedimentation rate (ESR).

Methods: 30 patients with TA fulfilling ACR 1990 criteria and 20 healthy controls were included after seeking informed consent. NK cells (CD3-CD56+), NK-T cells (CD3+CD56+) and γδ-T cells (CD3+and γδTCR+) were surface stained in whole blood. For Th17 cells, 500 μl blood+500 μl cRPMI was cultured for 6 hours in presence of 50 ng/ml PMA, 1 μg/ml ionomycin for activation and golgi plug 0.2 μM monansin was added in last 4 hours of culture. Surface staining was done with anti-CD3, CD4, and intracellular staining for IL-17. Frequencies of all cell types were analysed by flow cytometry. Th17 cells could not be assessed in one patient due to technical difficulties.

IL-17 and IL-23 were measured in serum by ELISA according to manufacturer’s instructions. The relation of studied cell populations and serum IL-17 and IL-23 was analysed with disease activity (assessed by Kerr criteria, ITAS2010 and ITASA). Non-parametric tests were used for analysis (results presented as median with inter-quartile range). This study was approved by the institute ethics committee.

Results:

Mean age of patients was 33.47±11.78 years (25 females); mean symptom duration was 7.1±5.3 years. 13 were not on immunosuppressive drugs. 12 patients had ITAS ≥ 4. Compared with normal, the percentage of Th17 cells was significantly expanded in patients with TA. No differences in other cell populations were found. Serum IL-17 and IL-23 (pg/mL) in patients were significantly higher than controls (Table 1).

 Subgroup analysis showed that the increased Th17 cells, serum IL-17 and IL-23 did not correlate with ESR, disease activity or medications.

Conclusion:

There is significant expansion of Th17 cells and elevation of serum IL-17 and IL-23 levels in patients with TA as compared to healthy controls. No relationship with disease activity could be demonstrated.

Table 1 – Gamma delta T cells, NK cells, NKT cells , Th17 cells, serum IL-17 and serum IL-23 in patients and controls (median with interquartile range in brackets)

 

Patients (30)

Healthy controls (20)

P value

Serum IL-17 (pg/mL)

6.2 (4.6-8.5)

3.9 (3.9-7.3)

0.004

Serum IL-23 (pg/mL)

15 (14.9-26.5)      

14.9 (14.9-14.9)

<0.0001

Th17 cells (%)

2.1 (1.5-3.2) (n=29)

0.75 (0.32-1.2)

<0.0001

Gamma delta T cells(%)

5.5 (3.9-7.1)

6 (2.7-9.9)

0.72

NK cells(%)

5.2 (3.6-8.7)

6.9 (4.3-9.3)

0.39

NKT cells(%)

3.7 (1.9-6.5)

2.4 (1.5-4.9)

0.12


Disclosure: R. Misra, None; D. P. Misra, None; S. Chaurasia, None.

To cite this abstract in AMA style:

Misra R, Misra DP, Chaurasia S. Increased Circulating Th17 Cells, Serum IL-17 and Serum IL-23 in Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/increased-circulating-th17-cells-serum-il-17-and-serum-il-23-in-takayasus-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-circulating-th17-cells-serum-il-17-and-serum-il-23-in-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology